Sarcoma  >>  balstilimab (AGEN2034) 
Welcome,         Profile    Billing    Logout  

3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
balstilimab (AGEN2034) / Agenus
NCT05864534: Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Recruiting
2
25
US
Balstilimab, BAL, Botensilimab, BOT, Liposomal Doxorubicin, DOX, Sonocloud-9 (SC-9), SC-9
Northwestern University, Agenus Inc., CarThera
Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme
05/26
08/26
NCT04028063: Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Recruiting
2
28
US
doxorubicin with AGEN1884 and AGEN2034
University of Colorado, Denver, Agenus Inc.
Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma
11/24
11/25
C-800-01, NCT03860272: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Recruiting
1
550
Europe, US
Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1
Agenus Inc.
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
 
 

Download Options